***Background.*** Neutropenic patients with hematologic malignancies rely on immediate, active antimicrobial therapy to combat bacterial infections, and thus are uniquely threatened by multidrug-resistant bacteria. Carbapenem-resistant Enterobacteriaceae (CRE) have emerged worldwide and are resistant to nearly all antimicrobial agents, but their impact on neutropenic patients is unknown.

***Methods.*** In order to assess the prevalence, risk factors, and outcomes of CRE bacteremia in neutropenic patients with hematologic malignancies, we reviewed all bloodstream infections (BSIs) from 2008-2012 in this population at New York-Presbyterian Hospital/Weill Cornell and Memorial Sloan-Kettering Cancer Center and conducted a case-control study. For each case of CRE BSI, three controls matched by study site and year were randomly selected among BSIs caused by other pathogens.

***Results.*** CRE caused 4.8% of Gram-negative bacteremias and 2.1% of all BSIs. Of the 42 episodes of CRE bacteremia, 31 (74%) were in patients with acute leukemia, 15 (36%) were in allogeneic stem cell transplant recipients, and 26 (62%) were in patients without prior carbapenem exposure. Independent risk factors for CRE bacteremia were exposure to β-lactam/β-lactamase inhibitors (BL-BLI; odds ratio \[OR\] = 3.7; *P* = 0.01) and trimethoprim-sulfamethoxazole (TMP-SMX; OR 6.0; *P* = 0.007), glucocorticoid use (OR 5.3; *P* = 0.001), and having a prior culture that grew CRE (OR 19.2; *P* = 0.01). Patients with CRE bacteremia were less likely than controls to receive active empirical therapy (14% vs 56%, *P* \< 0.001) and had longer delays until receipt of active therapy (median hours: 52 vs 5, *P* \< 0.001). They also had higher 30-day (51% vs 25%, *P* = 0.001) and BSI-related (49% vs 16%, *P* \< 0.001) mortality rates, with a median of 3 days from bacteremia onset until death. The six cases of CRE bacteremia that received active empirical therapy had a lower 30-day mortality rate than that of the 36 others that did not (17% vs 58%; *P* = 0.09).

***Conclusion.*** CRE are emerging as lethal causes of bacteremia in neutropenic patients with hematologic malignancies. Exposures to BL-BLI, TMP-SMX, and glucocorticoids and having a prior culture that grew CRE are risk factors for CRE bacteremia in this population. New strategies are needed to shorten the delay until administration of CRE-active agents and mitigate this emerging threat.
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